TrialAssure earns ISO 27001:2022 certification for AI life sciences software
TrialAssure said it has secured ISO/IEC 27001:2022 certification for its information security management system as pharmaceutical and biotech companies adopt more AI in regulated workflows. The certification is meant to reassure customers that the company’s clinical trial and AI software is backed by independently audited security controls.
Why it matters: - TrialAssure’s certification signals stronger security credentials for AI tools used in drug development and clinical trial workflows. - Pharmaceutical and biotechnology companies are putting more sensitive data into AI systems, making information security a core buying requirement. - The certification may help TrialAssure stand out as customers look for technology partners that can support compliance and transparency without increasing risk.
What happened: - TrialAssure announced it has achieved ISO/IEC 27001:2022 certification for its Information Security Management System. - The company said the certification was issued on August 20, 2026, in Canton, Michigan. - ISO/IEC 27001:2022 is an internationally recognized standard for managing information security risk and protecting sensitive data.
The details: - The certification means TrialAssure’s information security program was independently audited and verified against the standard. - TrialAssure said the certification supports its portfolio of AI and clinical technology products. - The portfolio includes LINK AI for AI-assisted medical writing. - The portfolio includes ANONYMIZE for document and data anonymization. - The portfolio includes REGISTRY for clinical trial disclosure. - The broader suite is designed to help life sciences organizations simplify compliance, improve operational efficiency, and support global transparency requirements. - TrialAssure also offers more information about its secure AI and clinical technology solutions.
Between the lines: - The announcement comes as AI adoption grows across medical writing, regulatory operations, and trial transparency. - TrialAssure is framing security as part of the product itself, not as a separate IT concern. - The company is positioning trusted infrastructure as a competitive advantage in regulated life sciences markets.
What’s next: - TrialAssure is expected to use the certification to reinforce customer confidence as it expands AI use cases across regulated workflows. - The company’s security posture could become part of future sales and deployment conversations with sponsors and research organizations. - TrialAssure said the certification is an important milestone as it works to deliver secure AI tools for drug development.
The bottom line: - TrialAssure is betting that trusted security will be just as important as AI performance in life sciences software adoption.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Sci-Tech News Network
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.